コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 a cardinal symptom of drug addiction (severe substance use disorder).
2 unipolar depression, anxiety disorders, and substance use disorders).
3 me psychopathology (depressive, anxiety, and substance use disorders).
4 ter risk of relapse and treatment failure in substance use disorder.
5 a blurred boundary between schizophrenia and substance use disorder.
6 tes of comorbidity between schizophrenia and substance use disorder.
7 , other substance use, and family history of substance use disorder.
8 ward, which might heighten susceptibility to substance use disorder.
9 lated reward seeking is a central feature of substance use disorder.
10 ased mortality and are more likely to have a substance use disorder.
11 riteria for a DSM-IV depressive, anxiety, or substance use disorder.
12 attention-deficit/hyperactivity disorder and substance use disorder.
13 18 years who have not been diagnosed with a substance use disorder.
14 veryone who tries addictive drugs develops a substance use disorder.
15 ne (METH), increase relapse vulnerability to substance use disorder.
16 tablished interventions aimed at people with substance use disorder.
17 ion in behavioral models of vulnerability to substance use disorder.
18 tive processes governing memory retrieval to substance use disorder.
19 nts with ADHD with preexisting depression or substance use disorder.
20 n many neuropsychiatric disorders, including substance use disorder.
21 iatric, anxiety, depressive, personality, or substance use disorders.
22 ) for mood disorders to 3.91 (3.87-3.94) for substance use disorders.
23 ariety of adverse health outcomes, including substance use disorders.
24 resents a viable target for the treatment of substance use disorders.
25 ing disorders that is comorbid with mood and substance use disorders.
26 opment in adolescents' natural resilience to substance use disorders.
27 have efficacy for the treatment of mood and substance use disorders.
28 e is associated with Parkinson's disease and substance use disorders.
29 ng high rates of mental health disorders and substance use disorders.
30 ion, schizophrenia, cognitive disorders, and substance use disorders.
31 ntrolling for potential confounders, such as substance use disorders.
32 been implicated as potential medications for substance use disorders.
33 new directions in medication development for substance use disorders.
34 ating the vulnerability to substance use and substance use disorders.
35 understudied component of both gambling and substance use disorders.
36 e experiences who are at risk for developing substance use disorders.
37 populations, potentially increasing risk for substance use disorders.
38 re the most common mental, neurological, and substance use disorders.
39 externalizing behaviors relevant to mood and substance use disorders.
40 between 12-month and lifetime DUD and other substance use disorders.
41 ssociated with risk for alcoholism and other substance use disorders.
42 system disorders including schizophrenia and substance use disorders.
43 costly, chronic diseases such as obesity and substance use disorders.
44 with early life stress and with anxiety and substance use disorders.
45 ssociated with an increased risk for several substance use disorders.
46 sychiatric illnesses in adulthood, including substance use disorders.
47 en investigated as a potential treatment for substance use disorders.
48 re are few effective strategies for treating substance use disorders.
49 by stress, such as depressive disorders and substance use disorders.
50 ities in risk-taking in the reward domain to substance use disorders.
51 development of pharmacotherapeutics to treat substance use disorders.
52 %) in women were potentially attributable to substance use disorders.
53 nds to co-occur with other disorders such as substance use disorders.
54 dual diagnosis and seek to prevent or treat substance use disorders.
55 a target for developing medications to treat substance use disorders.
56 odegeneration, dopamine neuron function, and substance use disorders.
57 hyperactivity disorder, mood disorders, and substance use disorders.
58 as a clinician-extender in the treatment of substance use disorders.
59 otential therapeutic target for treatment of substance use disorders.
60 among patients diagnosed with or at risk of substance use disorders.
61 ance use disorders compared to those without substance use disorders.
62 ychiatric disorders including depression and substance use disorders.
63 o advance the science and treatment of other substance use disorders.
64 e therapeutics for the treatment of mood and substance use disorders.
65 prison intake and geographic variations for substance use disorders.
66 tus, and the presence of current or previous substance use disorders.
67 ith neuropsychiatric disorders, particularly substance use disorders.
68 ding schizophrenia, Parkinson's disease, and substance use disorders.
69 t neural systems relevant to psychiatric and substance use disorders.
70 onditions, including Alzheimer's disease and substance use disorders.
71 lopment, and neurological, mental health and substance-use disorders.
72 binge eating had a similar pattern to other substance-use disorders.
73 craving, a key factor in the maintenance of substance-use disorders.
74 isorder show greater risk-taking, similar to substance-use disorders.
75 nd impact of neurological, mental health and substance-use disorders.
76 lect risk for a diversity of psychiatric and substance use disorders?
77 % CI, 77%-96%) and 94% (95% CI, 89%-96%) for substance use disorders, 100% and 94% (95% CI, 90%-96%)
78 hizophrenia (168.3 per 100000 person-years), substance use disorder (116.5 per 100000 person-years),
80 y disorders (39.9% compared with 21.8%), and substance use disorders (19.9% compared with 10.1%), but
81 onal defiant disorder, conduct disorder, and substance use disorder, ADHD remained associated with in
82 nabis use disorder was associated with other substance use disorders, affective disorders, anxiety, a
83 7), conduct disorder (97.1 [0.82]; P = .02), substance use disorders (alcohol abuse, 96.5 [0.67]; P <
86 ly higher rates of severe mental illness and substance use disorders among prisoners than in the gene
87 AHR, 2.0; 95% CI, 1.4-2.8; reference cohort, substance use disorder), an outpatient diagnosis of schi
88 , an ongoing study of youth at high risk for substance use disorder and a contrast sample of control
89 role of opioids in cancer pain, the risk of substance use disorder and methods to achieve the right
91 er rather than specific risks for individual substance use disorders and adds to increasing evidence
92 he Diagnostic Interview Schedule Version IV (substance use disorders and antisocial personality disor
93 ng adolescents, promoting the development of substance use disorders and compromised decision-making
94 orders, bipolar disorder, schizophrenia, and substance use disorders and convictions for violent crim
95 and SVM-based classifier in the diagnosis of substance use disorders and furthering an understanding
97 g adults' use of hospital-based services for substance use disorders and non-substance use psychiatri
99 sk of IPV against women in men when comorbid substance use disorders and personality disorders were p
101 ene at the center of the strongest QTL, with substance use disorders and related behavioral phenotype
102 rs identify individuals at greatest risk for substance use disorders and target intervention strategi
103 tions in understanding its relationship with substance use disorders and underlying mechanisms of the
106 stimulant that has recently been linked to a substance-use disorder and 'pharmacoterrorism' in the Mi
108 s to prevent mental health, neurological and substance-use disorders and develop effective interventi
109 a contributory factor in the maintenance of substance-use disorders and may relate to treatment resp
110 pulations (college students, patients with a substance use disorder, and Amazon Mechanical Turk worke
111 rbidities, a history of depression, anxiety, substance use disorder, and chronic pain (all P < 0.01).
112 solimbic dopamine projections in motivation, substance use disorder, and drug relapse, we examined th
113 s needle and syringe programs, treatment for substance use disorder, and HIV and HCV treatment, as we
114 trajectories are associated with symptoms of substance use disorder, and identity factors associated
115 roblem gambling is also highly comorbid with substance use disorder, and many commercial gambling pro
116 e disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorder) and a
117 e disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorders in re
118 njuries, major depression, bipolar disorder, substance use disorder, and other mental health conditio
119 g number and proportion of organ donors with substance use disorder, and particularly injection drug
120 al injuries to patients with past or current substance use disorder, and restricting duration to 7 da
122 midst of an unprecedented epidemic of opioid substance use disorder, and while pharmacotherapies incl
123 s, 100% and 94% (95% CI, 90%-96%) for severe substance use disorders, and 75% (95% CI, 52%-89%) and 9
124 isorders, obsessive-compulsive disorder, and substance use disorders, and medical conditions, includi
125 e a role, such as persistent pain, mood, and substance use disorders, and responses to their treatmen
126 to mental disorders, neurological disorders, substance use disorders, and self-harm (MNSS) in the Ame
127 were used to assess affective, anxiety, and substance use disorders, and self-report measures of dis
129 cur with major depression, alcohol and other substance-use disorders, and personality disorders.
130 hazards; climate change; maternal mortality; substance use disorders; and the health risks associated
131 Unlike most medications for the treatment of substance use disorders, anecdotal reports suggest that
132 eating disorders, autism spectrum disorder, substance use disorders, anxiety disorders, and personal
135 revalence data for mental, neurological, and substance use disorders are essential for evidence-based
136 s for depression, patients with co-occurring substance use disorders are less likely to receive guide
138 More data for mental, neurological, and substance use disorders are needed for India and China b
139 like behavior in rats.SIGNIFICANCE STATEMENT Substance-use disorders are often characterized as "habi
140 on deficit hyperactivity disorder (ADHD) and substance use disorders, are characterized by deficits i
141 r persistent opioid use with past or current substance use disorder (ARI, 10.5% [CI, 4.2% to 19.8%]),
142 ation and prevention services among men with substance use disorders as an approach to reduce the pre
143 of perpetrating IPV towards women, and that substance use disorders, as principal or comorbid diagno
144 hest in people diagnosed with a psychoactive substance use disorder at first discharge (cumulative in
145 umatic stress disorder (PTSD) co-occurs with substance use disorders at high rates, but the neurobiol
146 in-maintained outpatients from the Centre of Substance Use Disorders at the University Hospital of Ps
147 nal disruption in individuals with an opioid substance use disorder, at both behavioral and brain act
148 different levels of severity in mood/anxiety/substance use disorders based on the dimensional NIMH Re
149 of the increase in mental, neurological, and substance use disorder burden from 1990 to 2013 (44%) th
151 d behavioral addiction, with similarities to substance use disorders but without the confounding effe
152 els of comorbidity between schizophrenia and substance use disorder, but little is known about the ge
153 dose is an opportunity to identify and treat substance use disorders, but treatment patterns after th
155 , injury and neurological, mental health and substance-use disorders can result, further challenging
157 We obtained information about treatment for substance use disorders (categorised into treatment for
158 from NCDs, whereas premature mortality from substance use disorders, chronic kidney disease and acut
159 seases, 10th revision (ICD-10), diagnosis of substance use disorder (codes F10.X-19.X), emigration, d
160 ntary roles that the infectious diseases and substance use disorder communities can play in addressin
161 or patients with co-occurring depression and substance use disorders compared to those without substa
162 9) migrants had similarly lower rates of all substance use disorders compared with Swedish-born indiv
163 episodes and Wave 2 depression, anxiety and substance use disorders controlling for background chara
165 ducted analyses that were adjusted for other substance use disorder criteria in a single nucleotide p
166 c Genomics Consortium were computed in three substance use disorder datasets: the Collaborative Genet
168 trong associations were observed between any substance use disorder diagnosis and the polygenic risk
169 mographic characteristics, family history of substance use disorder, disturbed family environment, ch
170 e is a strong risk factor for development of substance use disorders during adulthood, especially lat
171 i.e., emergency department visits related to substance use disorders) during months in which patients
173 of homelessness, imprisonment, sex work, or substance use disorder (excluding cannabis and alcohol u
174 reports suggest that females diagnosed with substance use disorder experience enhanced relapse vulne
175 pared with Swedish-born individuals, for all substance use disorders (F10.X-19.X), alcohol use disord
176 This issue provides a clinical overview of substance use disorders, focusing on epidemiology, preve
177 lence estimates of severe mental illness and substance use disorders for 14 527 prisoners from 13 LMI
178 s of the burden of mental, neurological, and substance use disorders for China and India from the Glo
179 ls (95% UI) for 15 mental, neurological, and substance use disorders for China and India in 1990 and
181 y, patients with co-occurring depression and substance use disorders had 13% lower odds (adjusted odd
182 epressant treatment, such that patients with substance use disorders had 21% lower odds of guideline-
183 research agenda for global mental health and substance-use disorders has been largely driven by the e
184 that young people at familial high risk for substance use disorders have decreased dopamine response
185 ent treatment of co-occurring depression and substance use disorders; however, the degree to which pa
186 young fathers) were at an increased risk for substance use disorders, hyperkinetic disorders, and men
187 ation patterns for mental, neurological, and substance use disorders identified in China and India em
188 isorder, and obsessive-compulsive disorder), substance use disorder (ie, drug abuse or dependence and
190 e association between mortality and lifetime substance use disorder in patients with schizophrenia, b
191 ssion treatment to patients with and without substance use disorders in a large integrated health car
192 or the most common mental, neurological, and substance use disorders in China and India from the Glob
193 the prevalence of mental, neurological, and substance use disorders in China and India published up
194 rojected burden of mental, neurological, and substance use disorders in China and India warrants the
195 l differences) and mental, neurological, and substance use disorders in China and India, the most pop
196 the prevalence of severe mental illness and substance use disorders in incarcerated individuals in L
198 Our findings suggest that lower rates of substance use disorders in migrants and refugees may ref
200 strongly associated with increased rates of substance use disorders in the Swedish-born population (
201 spondents, was significantly associated with substance use disorders in wave 2 (2004-2005) (any subst
202 n and effective treatment of psychiatric and substance use disorders in women with ALD may improve th
203 at reducing neurological, mental health and substance-use disorders in adolescence, which is a pivot
204 neurological, psychiatric, developmental and substance-use disorders in low- and middle-income countr
205 onal defiant disorder, conduct disorder, and substance use disorder increased the MRR even further.
207 merican College of Physicians maintains that substance use disorder is a treatable chronic medical co
209 t that comorbidity between schizophrenia and substance use disorder is partially attributable to shar
212 rs correlated with mental, neurological, and substance use disorders is urgently needed to help reduc
214 he large and increasing burden of mental and substance use disorders, its association with social dis
215 th all examined forms of psychopathology and substance use disorders, latent variable indirect effect
216 between 12-month and lifetime AUD and other substance use disorders, major depressive and bipolar I
218 complex interplay between mental health and substance-use disorders, medical conditions, and biologi
219 le in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment
220 69), co-morbid depression/anxiety (N = 153), substance use disorders (N = 131), and eating disorders
221 h comorbid anxiety disorders, depression, or substance use disorders, OCD was still associated with i
222 nce use disorders in wave 2 (2004-2005) (any substance use disorder: odds ratio [OR], 6.2; 95% CI, 4.
223 for cause-specific mortality associated with substance use disorder of alcohol, cannabis, or hard dru
224 In bipolar disorder or depression, only substance use disorders of alcohol (bipolar disorder, HR
225 CI, 1.0-1.9; P = .04) and decreased risk of substance use disorders (OR, 0.6; 95% CI, 0.3-0.9; P = .
226 , anxiety (OR, 1.57; 95% CI, 0.40-6.09), and substance use disorders (OR, 1.64; 95% CI, 0.24-11.17) d
227 ose most in need, problems with treatment of substance use disorders, overuse of opioid medications,
228 ound in many psychiatric disorders including substance use disorders, pathological gambling, and atte
229 f clinical overlap of mania with anxiety and substance use disorders provide a basis for re-examining
230 ogical profiles of mental, neurological, and substance use disorders provides opportunities for the i
231 different between ADHD and ASD only for the substance use disorder proxies and personality traits (p
232 y is most consistent with a general risk for substance use disorder rather than specific risks for in
233 ; however, the degree to which patients with substance use disorders receive guideline-concordant tre
234 sion: homeless populations, individuals with substance use disorders, sex workers, and imprisoned ind
235 that homeless populations, individuals with substance use disorders, sex workers, and imprisoned ind
236 on, suggest that a D3 antagonism strategy in substance use disorders should consider FAAH C385A polym
237 provision of care to those with co-occurring substance use disorders should focus on clinician-based
238 ior studies have shown that individuals with substance use disorders show greater discounting (sugges
242 based pharmacological therapies for treating substance use disorders, such as opioid agonist treatmen
243 olled 801 persons living with HIV (PLWH) and substance use disorder (SUD) from 11 hospitals across th
246 rug use increase vulnerability to relapse in substance use disorder (SUD), and there are no pharmacot
248 s of similar heritabilities, the progress of substance use disorders (SUD) genetics has been slow.
249 emic of opioid use disorders (OUD) and other substance use disorders (SUD) in the United States (US).
253 ircadian disruptions are a common symptom of substance use disorders (SUDs) and chronic exposure to d
254 xperiencing linked epidemics (a syndemic) of substance use disorders (SUDs) and infections associated
259 well trained subjects.SIGNIFICANCE STATEMENT Substance use disorders (SUDs) may result from a failure
261 ial comorbidity between stress disorders and substance use disorders (SUDs), and acute stress augment
266 r depressive disorder, anxiety disorder, and substance use disorder (suicide attempts: 1.82 [1.72-1.9
267 ificantly greater odds of having two or more substance use disorder symptoms at age 35 years, especia
269 al illness is far higher in individuals with substance use disorders than in those without, particula
270 Neurological, psychiatric, developmental and substance-use disorders that result from, or are worsene
271 are common neural characteristics with other substance use disorders, that could inform prevention an
272 of stigmatization of persons with mental and substance use disorders through blanket reporting laws.
273 ith those from prior neuroimaging studies in substance-use disorders, thus raising the possibility th
274 e using drugs but do not meet criteria for a substance use disorder to reduce or stop their use.
275 pecialists, including increasing training in substance use disorder treatment among infectious diseas
276 tudy participants received a written list of substance use disorder treatment and mutual help resourc
278 ice systems, modeled an average efficacy for substance use disorder treatment, and did not include co
279 nsurance coverage, access to healthcare, and substance use disorder treatment, for many Americans.
280 increasingly promoted to engage patients in substance use disorders treatment and HIV care, but ther
281 g the opioid epidemic, insurance coverage of substance use disorders treatment, education and workfor
283 m 2013 to 2025 for mental, neurological, and substance use disorders using United Nations population
284 chizophrenia, the SMR in those with lifetime substance use disorder was 8.46 (95% CI 8.14-8.79), comp
285 contrast, resilience against a diagnosis of substance use disorder was associated with hyperconnecti
288 s, or patients with high rates of concurrent substance use disorder) was 27% (95% CI, 18% to 37%).
291 Ys attributable to mental, neurological, and substance use disorders were found in China and India (6
292 ial correlates and mental, neurological, and substance use disorders were not consistent with those r
294 d 10 years, with the exception of eating and substance use disorders, which began in adolescence (int
295 , it is unclear whether this also applies to substance use disorders, which we investigated in a nati
296 authors assessed the association of comorbid substance use disorders with guideline-concordant depres
297 oked for papers on mental, neurological, and substance use disorders with location identifiers and so
298 njuries, motor vehicle accidents, education, substance use disorder), with estimates suggesting relat
299 rden attributed to mental, neurological, and substance use disorders within these two countries is es